scispace - formally typeset
G

Gaurav Goyal

Researcher at University of Alabama at Birmingham

Publications -  122
Citations -  1530

Gaurav Goyal is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 81 publications receiving 731 citations. Previous affiliations of Gaurav Goyal include Mayo Clinic & Creighton University Medical Center.

Papers
More filters
Journal ArticleDOI

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

TL;DR: These guidelines for the clinical, laboratory, histologic, and radiographic evaluation of ECD patients along with treatment recommendations based on clinical experience and review of literature in the molecular era are presented.
Journal ArticleDOI

The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease

TL;DR: This consensus statement represents a joint document from a multidisciplinary group of physicians at Mayo Clinic who specialize in the management of adult histiocytic neoplasms and consists of evidence- and consensus-based recommendations on when to suspect these neoplasm and what tests to order for the diagnosis and initial evaluation.
Journal ArticleDOI

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease

TL;DR: It is demonstrated that Rosai-Dorfman disease has diverse clinical manifestations and outcomes, while this disease has been historically considered a benign entity, a subset of patients endures an aggressive course necessitating the use of systemic therapies.
Journal ArticleDOI

Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes.

TL;DR: HS is a rare hematopoietic neoplasm derived from non-Langerhans histiocytic cells of the monocyte/macrophage system that is diagnosed using immunohistochemistry markers, such as CD68, lysozyme, CD4, and CD163, on the tissue biopsies.
Journal ArticleDOI

Contemporary Management of Localized Resectable Pancreatic Cancer.

TL;DR: Accumulating evidence suggests that the neoadjuvant approach may improve R0 resection rate in localized resectables and borderline resectable diseases, and potentially downstage locally advanced disease to achieve surgical resection, though the impact on survival is to be determined.